US20110212082A1 - Method for producing tablet comprising natural allicin - Google Patents
Method for producing tablet comprising natural allicin Download PDFInfo
- Publication number
- US20110212082A1 US20110212082A1 US13/107,947 US201113107947A US2011212082A1 US 20110212082 A1 US20110212082 A1 US 20110212082A1 US 201113107947 A US201113107947 A US 201113107947A US 2011212082 A1 US2011212082 A1 US 2011212082A1
- Authority
- US
- United States
- Prior art keywords
- allicin
- tablet
- natural
- powder
- weight parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/105—Persulfides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to a method for producing a tablet comprising natural allicin.
- Natural allicin is a mixture mainly composed of diallyltrisulfide, diallyl disulfide, diallyl-thiosulfinate, ajoene, and vinyldithiins. Generally, the allicin content refers to the total amount of the above mentioned five active ingredients. Natural allicin is extracted from garlic and plays a role something like broad-spectrum antibiotics and a vascular cleaner orprotector. Thus, it exhibits strong medicinal functions.
- a daily intake of between 5 and 80 mg of allicin is enough for a grownup.
- the administered allicin must be large, for example, exceeding 200 mg per time per 10 kg of body weight.
- Conventional allicin tablets contain a limited dose of allicin, for example, 20 mg or 25 mg of allicin per piece, and the dosage is 2-3 times per day with 2-6 pieces per time.
- Many practices have proved the fact that the prevention and treatment effect on worse diseases caused by viruses or bacteria is poor when the intake amount does not exceed 120 mg each time for people. Obviously, the dosage amount is not enough for preventing and treating diseases.
- administering a large amount of allicin one time is harmful to body.
- a tablet that comprises high content of allicin can be administered according to the body weight of a human in need thereof, involves no artificial chemicals, and exhibits good effect on anti-bacteria, anti-inflammation, and anti-virus.
- a tablet comprising 1,000 weight parts of 21-90% natural allicin powder, 10-30 weight parts of 50-95% sesamin, 10-30 weight parts of 50-95% IgY or IgG, and a release agent, the allicin content of the tablet being 200-800 mg/g.
- a tablet comprising 1,000 weight parts of 62-80% natural allicin powder, 20-80 weight parts of 50-95% sesamin, 20-80 weight parts of 50-95% IgY or IgG, 38-460 weight parts of starch, 100-1500 weight parts of garlic powder, and a release agent, the allicin content of the tablet being 200-600 mg/g.
- the release agent is magnesium stearate.
- the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-80 weight parts of 50-95% sesamin, 20-80 weight parts of 50-95% IgY or IgG, 340-460 weight parts of starch, 550-1500 weight parts of garlic powder, and 6 weight parts of magnesium stearate, and the allicin content of the tablet is 200-400 mg/g.
- the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-70 weight parts of 50-95% sesamin, 20-70 weight parts of 50-95% IgY or IgG, 80-460 weight parts of starch, 460-550 weight parts of garlic powder, and 4 weight parts of magnesium stearate, and the allicin content of the tablet is 300-500 mg/g.
- the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-50 weight parts of 50-95% sesamin, 20-50 weight parts of 50-95% IgY or IgG, 38-80 weight parts of starch, 200-460 weight parts of garlic powder, and 3 weight parts of magnesium stearate, and the allicin content of the tablet is 400-600 mg/g.
- the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-40 weight parts of 50-95% sesamin, 20-40 weight parts of 50-95% IgY or IgG, 38 weight parts of starch, 100-190 weight parts of garlic powder, 2 weight parts of magnesium stearate, and 10-100 weight parts of a cool or cold food additive, and the allicin content of the tablet is 400-600 mg/g.
- the cool or cold food additive is corn, wheat, barley, buckwheat, coix Seed, millet, mung bean, green bean sprouts, bitter melon, white fungus, seaweed, lettuce, aloe vera, white radish, asparagus, celery, water bamboo, coriander, white gourd, lily, towel gourd, spinach, amaranth, water spinach, fern, dandelion, clover blossom, sugar beet, sweet potato, konjak, water pack, eggplant, daylily, mushroom, cucumber, watermelon, melon, banana, rape, water chestnuts, water chestnut meat, lotus root, lotus seed, nelumbinis embryo, green tea, chrysanthemum, honeysuckle, apple, pear, orange, persimmon, hylocereusundatus fruit, star fruit, mangosteen, strawberries, loquat, cherry tomato, medlar, grapefruit, kiwi fruit
- the allicin content of the natural allicin power is 65-75%.
- the preparation method of the cool or cold food additive comprises grinding a raw material, extracting with liquor, filtering, removing residue and alcohol, and freeze-dryingto yield a powder or powder block.
- the 21-90% natural allicin powder was purchased from Hangzhou Shenzhou Earth Ecology Culture Institute.
- the natural allicin tablet is particularly suitable for humans with a cool- or cold-natured body.
- the above-mentioned cool or cold food additive can be added to the tablet. If the tablet comprises no cool or cold food additive, humans with a hot-natured body can eat sufficient cool or cold food when administering the tablet.
- a method for producing the allicin tablet comprises mixing the materials, uniformly stirring, and tabletting.
- Another method for producing the allicin tablet comprises mixing and uniformly stirring starch, garlic powder, and natural allicin powder, adding natural sesamin, Ig Y or Ig G, the release agent, and the cool or cold food additive, uniformly stirring, and tabletting.
- the release agent ensures the molds to be easily released and not sticky in the process of tabletting, the addition amount thereof is not related to the allicin content.
- the prepared allicin tablet is 1,000 mg/piece (1 g/piece), with allicin content of 200-700 mg/piece.
- the tablet can be administered according to body weight, i.e., one piece/10 kg body weight, 2-3 times per day.
- the allicin tablet has high content of allicin. Clinical applications have shown that for a seriously-ill patient, natural allicin can weaken the diseases but the administered dosage must be large. Generally, the dosage is 200-700 mg/10 kg body weight. For example, for a person with weight body of 50 kg, the oral dosage of natural allicin should be 1,000-3,500 mg per time, and 2-3 times a day.
- the allicin tablet can effectively kill inflammation, viruses, and infectious bacteria, without side effects and drug resistance. Thus, it is very safe and moderate.
- the allicin, sesamin, and IgG or IgY are compatible with each other and can be administered largely within an effective dose but cause no side effects to human body.
- the ingredients that are admixed with allicin and the proportions thereof are critical to ensuring optimal health benefits without side effects.
- the invention of the allicin tablet frees people from the over-dependence on chemical antibiotics as soon as possible.
- FIGS. 1-4 show HPLC (High performance liquid chromatography) traces of an allicin powder according to one embodiment of the invention.
- the 30-90% natural allicin powder used in following examples is produced and sold by Hangzhou Shenzhou Earth Ecology Culture Institute with a concentration of 30-90%.
- a sample is examined by Zhejiang University and Zhejiang Food Quality Supervision and Inspection Station. The examination results are listed in Tables 1-3.
- the natural allicin powder is milk white, light yellow, or brown.
- the measurement result of diallyltrisulfide is shown in FIGS. 1-4 in which the peak value represents the content of C 6 H 10 S 3 .
- 1,000 g of 65-70% natural allicin powder, 350 g of starch, and 1,500 of a garlic powder were mixed and stirred to yield a uniform mixture.
- 60 g of 70% natural sesamin, 60 g of 80% IgY, and 6 g of magnesium stearate were added, stirred uniformly, and tabletted.
- the resultant mixture was 2,976 g in weight and tabletted into 2,976 pieces. Each piece was 1 g, with allicin content exceeding 200 mg, generally between 218 and 235 mg.
- 1,000 g of 65-70% natural allicin powder, 38 g of starch, and 160 of a garlic powder were mixed and stirred to yield a uniform mixture.
- 20 g of 70% natural sesamin, 20 g of 80% IgY, 40 g of a 70% cool food additive, and 2 g of magnesium stearate were added, stirred uniformly, and tabletted.
- the resultant mixture was 1,280 g in weight and tabletted into 1,280 pieces. Each piece was 1 g, with allicin content exceeding 500 mg, generally between 508 and 547 mg.
- the natural allicin tablet was administered to nine patients catching a cold. After an hour, cold symptoms were alleviated. After three times' administration, the patients recovered completely.
- a liver and intestinal cancer patient was administered with eight bottles of the allicin tablet of the invention and twelve bottles of common allicin tablet. The disease weakened with passing day and the liver ache almost disappeared.
- a patient suffering from prostatitis was administered with the allicin tablet of the invention. One week later, the disease weakened.
- a patient suffering from an inflamed and aching tonsil with fever was administered with the allicin tablet of the invention. Half an hour later, the disease weakened. Four hours later, the allicin tablet was administered again. Soon, the fever and inflammation disappeared.
- the allicin tablet has capability of anti-bacteria and anti-inflammation.
- the dosage should be large.
- the tablet has the characteristic of the highest allicin content per piece, the largest dosage administered safely and no side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A method for producing a tablet including mixing and uniformly stirring starch, garlic powder, and natural allicin powder to yield a mixture, adding natural sesamin, Ig Y or Ig G, and magnesium stearate to the mixture, uniformly stiffing, and tabletting. The allicin tablet has high allicin content and capability of anti-bacteria and anti-inflammation, and can be administered based on the body weight of an animal in need thereof but causes no side effects.
Description
- This application is a divisional of U.S. Ser. No. 12/943,034 filed on Nov. 10, 2010, now pending, which is a National Stage Application of International Patent Application No. PCT/CN2009/072602, with an international filing date of Jul. 2, 2009, which is based on Chinese Patent Application No. 200810062759.7, filed Jul. 3, 2008. The contents of all of these specifications are incorporated herein by reference.
- 1. Field of the Invention
- The invention relates to a method for producing a tablet comprising natural allicin.
- 2. Description of the Related Art
- Natural allicin is a mixture mainly composed of diallyltrisulfide, diallyl disulfide, diallyl-thiosulfinate, ajoene, and vinyldithiins. Generally, the allicin content refers to the total amount of the above mentioned five active ingredients. Natural allicin is extracted from garlic and plays a role something like broad-spectrum antibiotics and a vascular cleaner orprotector. Thus, it exhibits strong medicinal functions.
- As a vascular protector, a daily intake of between 5 and 80 mg of allicin is enough for a grownup. However, if functioning as broad-spectrum antibiotics to kill infectious viruses and bacteria, the administered allicin must be large, for example, exceeding 200 mg per time per 10 kg of body weight. Conventional allicin tablets contain a limited dose of allicin, for example, 20 mg or 25 mg of allicin per piece, and the dosage is 2-3 times per day with 2-6 pieces per time. Many practices have proved the fact that the prevention and treatment effect on worse diseases caused by viruses or bacteria is poor when the intake amount does not exceed 120 mg each time for people. Obviously, the dosage amount is not enough for preventing and treating diseases. However, administering a large amount of allicin one time is harmful to body. Experiments showed that a large amount of allicin collapsed the heart of mice or rabbits. If a human was administered with 700 mg or more of natural allicin (i.e, 1,000 mg of a 70% concentrated natural allicin extract) alone, the chest and abdomen swelled and made him uncomfortable. The more allicin was ingested, the larger the swelling that was observed. Thus, it is urgent to develop an allicin tablet which can be administered largely within an effective dosebut causes no harm to human body.
- In view of the above-described problems, it is one objective of the invention to provide a tablet that comprises high content of allicin, can be administered according to the body weight of a human in need thereof, involves no artificial chemicals, and exhibits good effect on anti-bacteria, anti-inflammation, and anti-virus.
- To achieve the above objectives, in accordance with one embodiment of the invention, there is provided a tablet comprising 1,000 weight parts of 21-90% natural allicin powder, 10-30 weight parts of 50-95% sesamin, 10-30 weight parts of 50-95% IgY or IgG, and a release agent, the allicin content of the tablet being 200-800 mg/g.
- In accordance with another embodiment of the invention, there is provided a tablet comprising 1,000 weight parts of 62-80% natural allicin powder, 20-80 weight parts of 50-95% sesamin, 20-80 weight parts of 50-95% IgY or IgG, 38-460 weight parts of starch, 100-1500 weight parts of garlic powder, and a release agent, the allicin content of the tablet being 200-600 mg/g.
- In a class of this embodiment, the release agent is magnesium stearate.
- In a class of this embodiment, the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-80 weight parts of 50-95% sesamin, 20-80 weight parts of 50-95% IgY or IgG, 340-460 weight parts of starch, 550-1500 weight parts of garlic powder, and 6 weight parts of magnesium stearate, and the allicin content of the tablet is 200-400 mg/g.
- In a class of this embodiment, the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-70 weight parts of 50-95% sesamin, 20-70 weight parts of 50-95% IgY or IgG, 80-460 weight parts of starch, 460-550 weight parts of garlic powder, and 4 weight parts of magnesium stearate, and the allicin content of the tablet is 300-500 mg/g.
- In a class of this embodiment, the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-50 weight parts of 50-95% sesamin, 20-50 weight parts of 50-95% IgY or IgG, 38-80 weight parts of starch, 200-460 weight parts of garlic powder, and 3 weight parts of magnesium stearate, and the allicin content of the tablet is 400-600 mg/g.
- In a class of this embodiment, the tablet comprises 1,000 weight parts of 62-80% natural allicin powder, 20-40 weight parts of 50-95% sesamin, 20-40 weight parts of 50-95% IgY or IgG, 38 weight parts of starch, 100-190 weight parts of garlic powder, 2 weight parts of magnesium stearate, and 10-100 weight parts of a cool or cold food additive, and the allicin content of the tablet is 400-600 mg/g.
- In a class of this embodiment, the cool or cold food additive is corn, wheat, barley, buckwheat, coix Seed, millet, mung bean, green bean sprouts, bitter melon, white fungus, seaweed, lettuce, aloe vera, white radish, asparagus, celery, water bamboo, coriander, white gourd, lily, towel gourd, spinach, amaranth, water spinach, fern, dandelion, clover blossom, sugar beet, sweet potato, konjak, water pack, eggplant, daylily, mushroom, cucumber, watermelon, melon, banana, rape, water chestnuts, water chestnut meat, lotus root, lotus seed, nelumbinis embryo, green tea, chrysanthemum, honeysuckle, apple, pear, orange, persimmon, hylocereusundatus fruit, star fruit, mangosteen, strawberries, loquat, cherry tomato, medlar, grapefruit, kiwi fruit, soft-shelled turtle, turtle, duck, frog, jellyfish, snail, crab, clam, mussel, snakehead, snail, snake, or a mixture thereof, among which an extract from mungbean sprout or lily is preferable. The extract content is 40-95%.
- In a class of this embodiment, the allicin content of the natural allicin power is 65-75%.
- The preparation method of the cool or cold food additive comprises grinding a raw material, extracting with liquor, filtering, removing residue and alcohol, and freeze-dryingto yield a powder or powder block.
- The 21-90% natural allicin powder was purchased from Hangzhou Shenzhou Earth Ecology Culture Institute.
- As far as traditional Chinese medicine is concerned, garlic is hot-natured, so the natural allicin tablet is particularly suitable for humans with a cool- or cold-natured body. For humans with a hot-natured body, the above-mentioned cool or cold food additive can be added to the tablet. If the tablet comprises no cool or cold food additive, humans with a hot-natured body can eat sufficient cool or cold food when administering the tablet.
- A method for producing the allicin tablet comprises mixing the materials, uniformly stirring, and tabletting.
- Another method for producing the allicin tablet comprises mixing and uniformly stirring starch, garlic powder, and natural allicin powder, adding natural sesamin, Ig Y or Ig G, the release agent, and the cool or cold food additive, uniformly stirring, and tabletting.
- The release agent ensures the molds to be easily released and not sticky in the process of tabletting, the addition amount thereof is not related to the allicin content.
- The prepared allicin tablet is 1,000 mg/piece (1 g/piece), with allicin content of 200-700 mg/piece. The tablet can be administered according to body weight, i.e., one piece/10 kg body weight, 2-3 times per day.
- The allicin tablet has high content of allicin. Clinical applications have shown that for a seriously-ill patient, natural allicin can weaken the diseases but the administered dosage must be large. Generally, the dosage is 200-700 mg/10 kg body weight. For example, for a person with weight body of 50 kg, the oral dosage of natural allicin should be 1,000-3,500 mg per time, and 2-3 times a day. The allicin tablet can effectively kill inflammation, viruses, and infectious bacteria, without side effects and drug resistance. Thus, it is very safe and moderate.
- Conventional Chinese medicine pays good attention to the compatibility of different active ingredients. Pure allicin extracted from garlicis separated from other components therein. Thus, when administering to human body alone, people fall into an unbalanced and uncoordinated state. The purer in concentration or higherin quantity of the allicin, the worse the balance and the coordination. However, after mixed with a garlic powder, the allicin seems to recombine with other components of the garlic. High content of allicin together with other trace elements and nutritious components protects human body harmoniously and effectively.
- Single allicin can prevent and weaken diseases caused by nearly all the bacteria or virus, but a few of cases showed some of bacteria or virus cannot be rooted up if intaking allicin singly. The addition of a little sesamin can reach the effect and the treatment effect comes much sooner. If a little IgG or IgY is added, the effect is much better. The allicin, sesamin, and IgG or IgY are compatible with each other and can be administered largely within an effective dose but cause no side effects to human body. The ingredients that are admixed with allicin and the proportions thereof are critical to ensuring optimal health benefits without side effects. The invention of the allicin tablet frees people from the over-dependence on chemical antibiotics as soon as possible.
- The invention is described herein below with reference to accompanying drawings, in which
FIGS. 1-4 show HPLC (High performance liquid chromatography) traces of an allicin powder according to one embodiment of the invention. - To further illustrate the invention, experiments detailing an allicin tablet, a preparation method, and the use thereof are described below. It should be noted that the following examples are intended to describe and not to limit the invention.
- The 30-90% natural allicin powder used in following examples is produced and sold by Hangzhou Shenzhou Earth Ecology Culture Institute with a concentration of 30-90%. A sample is examined by Zhejiang University and Zhejiang Food Quality Supervision and Inspection Station. The examination results are listed in Tables 1-3.
-
TABLE 1 Sensory evaluation of the natural allicin powder produced by Hangzhou Shenzhou Earth Ecology Culture Institute Items Results Appearance Light yellow solid powder Smell A little garlic smell, no odour Flavor A little garlic taste, no odour Degree of fineness 80 mesh - Due to different garlic origin or production time, the natural allicin powder is milk white, light yellow, or brown.
-
TABLE 2 Sanitary evaluation of the natural allicin powder produced by Hangzhou Shenzhou Earth Ecology Culture Institute Items Unit Standard value Measured value Results Negative % ≦9 0 Satisfied deviation of net content Impurity % / 0.05 Satisfied Moisture % <9 3.26 Satisfied Ash % ≦6 2.66 Satisfied Heavy metal mg/kg ≦5.0 1.03 Satisfied (Hg + Pb) CFU cfu/g <30000 <10 Satisfied E. coli MPN/100 g <90 <30 Satisfied Mould cfu/g <25 <10 Satisfied Yeast cfu/g <25 <10 Satisfied Pathogen / Prohibited Not found Satisfied -
TABLE 3 Content measurement of diallyltrisulfide(C6H10S3) of the natural allicin powder produced by Hangzhou Shenzhou Earth Ecology Culture Institute Sample Allicin content Allicin content Item dissolution rate in sample solution in sample solid Content of allicin 66% 66.5371% 43.91% - The measurement result of diallyltrisulfide is shown in
FIGS. 1-4 in which the peak value represents the content of C6H10 S3. - 500 g of 65-70% natural allicin powder, 230 g of starch, and 230 of a garlic powder were mixed and stirred to yield a uniform mixture. To the uniform mixture, 20 g of 65% natural sesamin, 20 g of 80% IgG, and 2 g of magnesium stearate were added, stirred uniformly, and tabletted. The resultant mixture was 1,002 g in weight and tabletted into 1,002 pieces. Each piece was 1 g, with allicin content exceeding 300 mg, generally between 324 and 350 mg.
- 1,000 g of 65-70% natural allicin powder, 20 g of 65% natural sesamin, 20 g of 80% IgY, and 2 g of magnesium stearate were mixed, stirred uniformly, and tabletted. The resultant mixture was 1,042 g in weight and tabletted into 1,042 pieces. Each piece was 1 g, with allicin content exceeding 600 mg, generally between 634 and 685 mg.
- 1,000 g of 65-70% natural allicin powder, 350 g of starch, and 1,500 of a garlic powder were mixed and stirred to yield a uniform mixture. To the uniform mixture, 60 g of 70% natural sesamin, 60 g of 80% IgY, and 6 g of magnesium stearate were added, stirred uniformly, and tabletted. The resultant mixture was 2,976 g in weight and tabletted into 2,976 pieces. Each piece was 1 g, with allicin content exceeding 200 mg, generally between 218 and 235 mg.
- 1,000 g of 65-70% natural allicin powder, 450 g of starch, and 550 of a garlic powder were mixed and stirred to yield a uniform mixture. To the uniform mixture, 40 g of 70% natural sesamin, 40 g of 80% IgY, and 4 g of magnesium stearate were added, stirred uniformly, and tabletted. The resultant mixture was 2,084 g in weight and tabletted into 2,084 pieces. Each piece was 1 g, with allicin content exceeding 300 mg, generally between 312 and 336 mg.
- 1,000 g of 65-70% natural allicin powder, 50 g of starch, and 450 of a garlic powder were mixed and stirred to yield a uniform mixture. To the uniform mixture, 30 g of 70% natural sesamin, 30 g of 80% IgY, and 3 g of magnesium stearate were added, stirred uniformly, and tabletted. The resultant mixture was 1,563 g in weight and tabletted into 1,563 pieces. Each piece was 1 g, with allicin content exceeding 400 mg, generally between 416 and 448 mg.
- 1,000 g of 65-70% natural allicin powder, 38 g of starch, and 160 of a garlic powder were mixed and stirred to yield a uniform mixture. To the uniform mixture, 20 g of 70% natural sesamin, 20 g of 80% IgY, 40 g of a 70% cool food additive, and 2 g of magnesium stearate were added, stirred uniformly, and tabletted. The resultant mixture was 1,280 g in weight and tabletted into 1,280 pieces. Each piece was 1 g, with allicin content exceeding 500 mg, generally between 508 and 547 mg.
- 18 white rabbits (all were 1 kg in body weight) suffering from bacillary dysentery were divided into three groups (Group A, B, and C) randomly. The rabbits were treated separately. The treatment method and the results are shown in Table 4.
-
TABLE 4 Group Treatment Results A 100 mg of an allicin tablet Diarrhea disappeared on the with allicin content of treatment day. After between 30 and 70 mg was administration on the next day, administered, a piece one all the six rabbits recovered time, three times per day. completely. B 100 mg of an allicin tablet Diarrhea weakened on the with allicin content less than treatment day. On the next day, 30 mg was administered, a diarrhea disappeared. On the 3rd piece one time, three times day, all the six rabbits recovered per day. completely. C No allicin was administered. All the six rabbits died. - Eight German shepherd puppies suffered from plague, two of which were treated with injections and medicine without allicin, finally died. The rest six were at their last gasp and could not stand up. The allicin tablet of the invention was administered to the six puppies, three times a day. On the first administration day, the puppies stood up, walked around, and took food. On the 3rd day, the puppies recovered completely, with good appetite and walked smoothly. In the process of treating the six puppies, no injections and medicine involved.
- The following are clinical cases about the treatment effect of the natural allicin tablet on patients.
- 1. The natural allicin tablet was administered to nine patients catching a cold. After an hour, cold symptoms were alleviated. After three times' administration, the patients recovered completely.
- 2. A nephritis patient had high content ofurine protein. After 15 days' administration of the natural allicin tablet, the urine protein content decreased greatly and fell into the normal range.
- 3. A patient almost recovered from leukemia after hospital treatment. However, the disease relapsed soon and worsened. He had a fever everyday and severe oral ulcer. The natural allicin tablet was administered to the patient. Three days later, his body temperature was back to normal and the oral ulcer disappeared.
- 4. A lymphoma patient experiencing chemotherapy had severe oral ulcer and could not eat. Nothing but the natural allicin tablet was administered to the patient. Four days later, the oral ulcer disappeared.
- 5. A nasopharyngeal carcinoma patient experiencing chemotherapyhad severe oral ulcer. Chinese medicine and anti-inflammatory drugs were tried but had no effect. The natural allicin tablet was administered to the patient. Four days later, the oral ulcer disappeared.
- 6. A liver and intestinal cancer patient was administered with eight bottles of the allicin tablet of the invention and twelve bottles of common allicin tablet. The disease weakened with passing day and the liver ache almost disappeared.
- 7. A patient whose liver ached sometimes for several days was administered with the allicin tablet of the invention. Two days later, the ache disappeared.
- 8. A patient had yellow and smellyleucorrhea. Many anti-inflammatory and anti-bacterial drugs were tried but had no effect. The natural allicin tablet was administered to the patient. Several days later, the inflammation disappeared.
- 9. Two patients suffering from stomach disease was administered with the allicin tablet of the invention. Several days later, the disease was allievated.
- 10. A diarrhea patient was administered with the allicin tablet of the invention. Several times later, the diarrhea disappeared.
- 11. Seven patients suffering from toothache which resulted in headache was administered with the allicin tablet of the invention. Several times later, the aches disappeared.
- 12. Two patients suffering from urinary tract infection were administered with the allicin tablet of the invention. Three times later, the disease disappeared.
- 13. Two patients having nasal obstruction were administered with the allicin tablet of the invention. Three times later, the disease disappeared.
- 14. A patient suffering from prostatitis was administered with the allicin tablet of the invention. One week later, the disease weakened.
- 15. A patient suffering from an inflamed and aching tonsil with fever was administered with the allicin tablet of the invention. Half an hour later, the disease weakened. Four hours later, the allicin tablet was administered again. Soon, the fever and inflammation disappeared.
- 16. A patient suffering from high fever was administered with the allicin tablet of the invention thrice within 15 hrs. Gradually, the fever disappeared.
- 17. Two girls suffered from high fever, oral and hand ulcer. They cried all the time and had no appetite. The allicin tablet of the invention was administered. After an hour, the girls calmed down and had appetite. In the following two days, some medicine and the tablet were administered and all the symptoms disappeared soon.
- These clinical cases show that the allicin tablet has capability of anti-bacteria and anti-inflammation. However, in use, the dosage should be large. In contrast to the allicin tablets in the prior art, the tablet has the characteristic of the highest allicin content per piece, the largest dosage administered safely and no side effects.
- While particular embodiments of the invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made without departing from the invention in its broader aspects, and therefore, the aim in the appended claims is to cover all such changes and modifications as fall within the true spirit and scope of the invention.
Claims (3)
1. A method for producing a tablet comprising 1,000 weight parts of 21-90% a natural allicin powder, 10-30 weight parts of 50-95% sesamin, 10-30 weight parts of 50-95% IgY or IgG, and a release agent, the allicin content of said tablet being 200-800 mg/g; the method comprising mixing and uniformly stiffing said starch, said garlic powder, and said natural allicin powder to yield a mixture, adding said natural sesamin, Ig Y or Ig G, and said magnesium stearate to said mixture, uniformly stiffing, and tabletting.
2. The method of claim 1 , further comprising adding a cool or cold food additive to said mixture.
3. The tablet of claim 2 , wherein said cool or cold food additive is an extract from mungbean sprout or lily.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/107,947 US20110212082A1 (en) | 2008-07-03 | 2011-05-15 | Method for producing tablet comprising natural allicin |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810062759.7 | 2008-07-03 | ||
CN200810062759A CN101342148B (en) | 2008-07-03 | 2008-07-03 | Quick-effective antimicrobial, anti-inflammation, antiviral hyperconcentrated natural allicin tablet and preparation method thereof |
PCT/CN2009/072602 WO2010000207A1 (en) | 2008-07-03 | 2009-07-02 | A natural allicin tablet and preparation method thereof |
US12/943,034 US8216617B2 (en) | 2008-07-03 | 2010-11-10 | Tablet comprising natural allicin and method for producing the same |
US13/107,947 US20110212082A1 (en) | 2008-07-03 | 2011-05-15 | Method for producing tablet comprising natural allicin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/943,034 Division US8216617B2 (en) | 2008-07-03 | 2010-11-10 | Tablet comprising natural allicin and method for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110212082A1 true US20110212082A1 (en) | 2011-09-01 |
Family
ID=40244342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/943,034 Active US8216617B2 (en) | 2008-07-03 | 2010-11-10 | Tablet comprising natural allicin and method for producing the same |
US13/107,947 Abandoned US20110212082A1 (en) | 2008-07-03 | 2011-05-15 | Method for producing tablet comprising natural allicin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/943,034 Active US8216617B2 (en) | 2008-07-03 | 2010-11-10 | Tablet comprising natural allicin and method for producing the same |
Country Status (10)
Country | Link |
---|---|
US (2) | US8216617B2 (en) |
EP (1) | EP2347757B1 (en) |
JP (1) | JP5709744B2 (en) |
CN (2) | CN101342148B (en) |
AU (1) | AU2009266205B2 (en) |
CA (1) | CA2729617C (en) |
DK (1) | DK2347757T3 (en) |
ES (1) | ES2400597T3 (en) |
PL (1) | PL2347757T3 (en) |
WO (1) | WO2010000207A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115887451A (en) * | 2023-01-05 | 2023-04-04 | 山东国邦药业有限公司 | Levamisole hydrochloride tablet and preparation method thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017032711A1 (en) * | 2015-08-21 | 2017-03-02 | Gratia Mundi Gmbh | Active combinations, compositions and methods for enhancing hair growth |
CN107296799A (en) * | 2017-07-05 | 2017-10-27 | 北京罗麦科技有限公司 | A kind of allicin tablet and preparation method thereof |
JP7198630B2 (en) | 2018-10-26 | 2023-01-04 | 小林製薬株式会社 | oral composition |
JPWO2020241814A1 (en) * | 2019-05-29 | 2020-12-03 | ||
CN112552387B (en) * | 2020-12-31 | 2022-11-11 | 山西大学 | Anti-tumor active protein of day lily and preparation method and application thereof |
WO2023128999A1 (en) * | 2021-12-28 | 2023-07-06 | Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi | Natural compounds with anti-inflammatory effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080275110A1 (en) * | 2004-12-28 | 2008-11-06 | Yoshiko Ono | Sesamin/Episesamin Compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58157722A (en) * | 1982-03-13 | 1983-09-19 | Green Cross Corp:The | Treating and preventing agent for inflammation |
JPH06227977A (en) * | 1993-02-01 | 1994-08-16 | Suntory Ltd | Active oxygen eliminating agent |
AU1928295A (en) * | 1994-02-25 | 1995-09-11 | New England Deaconess Hospital Corporation | Anti-inflammatory and infection protective effects of sesamin-based lignans |
CN1448129A (en) * | 2003-04-24 | 2003-10-15 | 中国人民解放军沈阳军区总医院 | Garlicin and garlic oil cyclodextrin derivatives inclusion compound and method for making same |
CN100350907C (en) * | 2004-03-10 | 2007-11-28 | 徐华 | Natural antioxidant with human immunity-enhancing and virus-preventing functions |
WO2008007728A1 (en) * | 2006-07-13 | 2008-01-17 | Kaneka Corporation | Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient |
JP2008105998A (en) * | 2006-10-25 | 2008-05-08 | Tm East:Kk | Health food consisting of mixed powder of msm, garlic and afa |
JP2008273874A (en) * | 2007-04-27 | 2008-11-13 | Fuji Chem Ind Co Ltd | External preparation for scalp |
-
2008
- 2008-07-03 CN CN200810062759A patent/CN101342148B/en active Active
-
2009
- 2009-07-02 WO PCT/CN2009/072602 patent/WO2010000207A1/en active Application Filing
- 2009-07-02 CA CA2729617A patent/CA2729617C/en active Active
- 2009-07-02 PL PL09771977T patent/PL2347757T3/en unknown
- 2009-07-02 DK DK09771977.7T patent/DK2347757T3/en active
- 2009-07-02 JP JP2011515076A patent/JP5709744B2/en active Active
- 2009-07-02 AU AU2009266205A patent/AU2009266205B2/en not_active Ceased
- 2009-07-02 ES ES09771977T patent/ES2400597T3/en active Active
- 2009-07-02 CN CN200910303931A patent/CN101683326A/en active Pending
- 2009-07-02 EP EP09771977A patent/EP2347757B1/en active Active
-
2010
- 2010-11-10 US US12/943,034 patent/US8216617B2/en active Active
-
2011
- 2011-05-15 US US13/107,947 patent/US20110212082A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080275110A1 (en) * | 2004-12-28 | 2008-11-06 | Yoshiko Ono | Sesamin/Episesamin Compositions |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115887451A (en) * | 2023-01-05 | 2023-04-04 | 山东国邦药业有限公司 | Levamisole hydrochloride tablet and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8216617B2 (en) | 2012-07-10 |
EP2347757B1 (en) | 2012-11-28 |
EP2347757A1 (en) | 2011-07-27 |
AU2009266205B2 (en) | 2013-12-19 |
EP2347757A4 (en) | 2012-05-09 |
CA2729617A1 (en) | 2010-01-07 |
AU2009266205A1 (en) | 2010-01-07 |
PL2347757T3 (en) | 2013-06-28 |
JP2011526255A (en) | 2011-10-06 |
US20110052568A1 (en) | 2011-03-03 |
CN101342148B (en) | 2012-09-05 |
DK2347757T3 (en) | 2013-03-18 |
JP5709744B2 (en) | 2015-04-30 |
CA2729617C (en) | 2018-02-27 |
CN101683326A (en) | 2010-03-31 |
WO2010000207A1 (en) | 2010-01-07 |
CN101342148A (en) | 2009-01-14 |
ES2400597T3 (en) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8216617B2 (en) | Tablet comprising natural allicin and method for producing the same | |
CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
CN109476701B (en) | Composition for protecting cells comprising cyclamic acid-proline as active ingredient | |
CN100446794C (en) | Chinese medicinal formulation for treating gastrointestinal disease | |
KR101829637B1 (en) | A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract | |
CN107184702A (en) | A kind of Chinese medicine composition for preventing and treating poultry proventriculitis ventriculitis and preparation method thereof | |
CN109224024A (en) | For preventing and treating the pharmaceutical composition and its application method of fresh-water fishes bacteria mixed infection | |
JP2015218145A (en) | TNF-α PRODUCTION INHIBITOR | |
WO2008010335A1 (en) | Plant extract having arthritis-preventive effect | |
Emmanuel et al. | COVID 19: Resveratrol as a Potential Supplement to Mitigate the Cardiotoxicity Associated with Chloroquine and Hydroxychloroquine Treatment | |
CN113577187A (en) | Anti-influenza traditional Chinese medicine composition, traditional Chinese medicine extract and preparation method and application thereof | |
KR20180086935A (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
CN105920377A (en) | Feed additive for control of soft-shelled turtle putred-skin disease and preparation method thereof | |
KR101559655B1 (en) | Composition comprising myricetin for inhibition of pancreatic lipase | |
CN1970068A (en) | Effervescence tablet for treating colpitis, preparation method and use thereof | |
Omodale et al. | Protective effect of aqueous root extract of Gongronema latifolium against paracetamol induced hepatotoxicity and chloroquine induced nephrotoxicity in rats | |
CN108815279A (en) | It is a kind of for treating the Chinese medicine composition and its preparation method and application of grouper vibrio fluvialis disease | |
CN107320533A (en) | A kind of Chinese medicine composition for preventing chicken to catch | |
CN104606627B (en) | A kind of pharmaceutical composition for treating grice diarrhoea and preparation method thereof | |
US20130337057A1 (en) | Novel herbal composition for the treatment of kidney stone and other urinary tract disorders | |
CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
CN103948591B (en) | A kind of slimming agents | |
Anionye et al. | Biochemical and histological Evaluation of the Ability of Yoyo Cleanser Bitters to Prevent Cardiovascular Diseases Induced in rats by a Combined High-salt and High-Fat Diet | |
CN106511819A (en) | Traditional Chinese medicinal composition used for fever abatement of animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |